Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

han 35 kg/m2. It is estimated that approximately two-thirds of patients with type 2 diabetes are overweight or obese, with a BMI less than 35 kg/m2. In addition, approximately three-quarters of individuals with BMI less than 35 kg/m2 without type 2 diabetes have dyslipidemia and/or hypertension.

Amylin's Approach to Obesity Research and Development

Currently, physicians and patients seeking prescription medications for weight loss have limited therapeutic options. New scientific advances have established the key role of neurohormones in the physiological regulation of appetite and energy balance, as well as the importance of studying the interaction among these hormones (within the brain) to uncover their full therapeutic potential. Amylin scientists discovered that combination treatment with neurohormones, such as amylin and leptin, can produce additive and synergistic weight loss in animal models. These findings formed the basis for Amylin's innovative integrated neurohormonal approach to the development of obesity treatments.

About Pramlintide/Metreleptin Combination Treatment

Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy metabolism and body weight. To date, more than 1,200 overweight or obese individuals have received metreleptin in clinical trials, several of which were 16 weeks or longer in duration. In an initial 24-week, Phase 2 clinical proof-of-concept study in 177 overweight or obese individuals (baseline
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... When ... has made a lasting impact on both agriculture and weed science around the globe. He ... techniques to benefit farmers. Thousands of students have followed in his footsteps and are now making ... ...
... results of this study will be presented during the ... June 3, 2009 COLUMBIA, Md., May 30 Lead ... from the University of Miami , evaluated whether ... determining rejection or infection in kidney transplant recipients. Patients ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... until they hatched 4.5 years later, according to a ... PLOS ONE by Bruce Robison from Monterey ... have a single reproductive period during their life, where ... eggs until they hatch. Shallow-water octopuses typically care for ... is known about the brooding of deep-sea species. Using ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... "Environmental Nanoparticles: Science, Ethics & Policy" on Nov. ... Center in Newark, Del. The registration deadline is ... co-sponsored by UD,s Center for Critical Zone Research ... will include presentations by nationally and internationally recognized ...
... the first critical steps in unraveling the mysteries of ... that afflicts 500,000 people worldwide each year and nearly ... An international team led by Murat Gunel, professor ... and chair of genetics, and a Howard Hughes Medical ...
... Conn. If climate disasters are to be averted, atmospheric carbon ... today, according to a study published in Open Atmospheric ... the United States, the United Kingdom and France. ... a planet similar to that on which civilization developed, an optimum ...
Cached Biology News:Workshop on environmental nanoparticles at UD, Nov. 10-11 2Yale researchers unravel mystery of brain aneurysms 2Revised theory suggests carbon dioxide levels already in danger zone 2